Leberschädigung unter Ocrelizumab (OCREVUS) Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.

#Leberschädigung unter #Ocrelizumab (OCREVUS)

Swissmedic stuft klinisch bedeutsame Leberschädigung ohne Virushepatitis-Nachweis als identifiziertes Risiko des Anti-CD20-Antikörpers bei #MS -Patienten ein.

www.arznei-telegramm.com/de/6459/lebe...

Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

#Roche #primaryprogressiveMS #MS #phase3trial #oralBTKinhibitor #fenebrutinib #primaryprogressivemultiplesclerosis #PPMS #Ocrevus #ocrelizumab #FENtrepidtrial #disabilityprogression #CD20targetingantibody #FENhance1trial #FENhance2trial #clinicalbenefit #diseasemodifyingtherapy
zurl.co/MGaVR

"Patients would come in and say, “Oh, I have crap gap.” I remember the first few times I thought, “What is this crap gap?” The patients are talking about it on social media, but when we Googled it, the only reference we could find to it was on Reddit."
www.ijmsc.org/view/ijmsc-a...
#ocrelizumab

Ocrelizumab number two done ✔️

Here is a selection of amazing #art from the staff gallery at Charing Cross Hospital and the Imperial College Trust - grateful for amazing doctors, nurses and hospital staff 🙏🏼
❤️
#ocrevus
#gratitude
#gallery
#ms
#ocrelizumab

“A single immune signal predicting 2-year #MS outcomes?😮🔍”
High #TNF mRNA = greater disability progression under #Ocrelizumab! @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share 🔗
www.mdpi.com/1422-0067/26...

Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...

“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...

“Could a blood-based #TNF signature reshape #MS therapy decisions?💡🩸⚡️” High baseline TNF linked to more disease activity on #Ocrelizumab! @mdpiopenaccess.bsky.social
#NeuroScience #ClinicalResearch Read, share, spread the insight!🔥
www.mdpi.com/1422-0067/26...

“A single immune signal predicting 2-year #MS outcomes?😮🔍” High #TNF mRNA = greater disability progression under #Ocrelizumab! @IJMS_MDPI @mdpiopenaccess.bsky.social
#Immunology #MSScience #TranslationalResearch
Check the findings + share! 🔗
www.mdpi.com/1422-0067/26...

“Ever wondered why some #MS patients thrive on #Ocrelizumab while others don’t? 👀🧬”
Baseline #TNF levels in #PBMCs quietly forecast treatment failure!📉 @mdpiopenaccess.bsky.social #MSResearch #Ocrelizumab #PrecisionMedicine
Dive in + share 👇
www.mdpi.com/1422-0067/26...

“What if one #Cytokine could predict who benefits from #Ocrelizumab? 🤔🔥”
High #TNF mRNA at baseline = higher #MS activity after 24 months!📈 @mdpiopenaccess.bsky.social
#MultipleSclerosis #Neuroimmunology #Biomarkers
Read more & share 👉
www.mdpi.com/1422-0067/26...

"The purpose of this study was to evaluate adherence to CDC #pneumococcal #vaccination recommendations for patients with MS receiving #ocrelizumab or #rituximab at an #MS center in an academic medical center before and after a nursing intervention."

doi.org/10.7224/1537...

#biosimilars #PolpharmaBiologics #MSPharma #gastroenterology #neurology #dermatology #MENA #vedolizumab #ocrelizumab #guselkumab #ulcerativecolitis #Crohnsdisease #multiplesclerosis #plaquepsoriasis #psoriaticarthritis #biosimilarmanufacturing #MS #PolpharmaBiologicsGroup
zurl.co/GJnQQ

Secondary Organising #Pneumonia Among Immunocompromised #MultipleSclerosis Patients Treated With #Ocrelizumab Following #COVID-19 Infection: Two Case Reports With Literature Review
onlinelibrary.wiley.com/doi/10.1002/...

Multiple Sclerosis Treatment Research Observatory Explore research articles and clinical trials for MS treatments and therapies

I was wondering who published more research related to #ocrelizumab. @gregory-ms.com has the answer: gregory-ms.com/observatory/...

#multipleSclerosis #MSChat #AskGregory

Hoi hoi, lange stilte hier. Probeer het weer op te pakken. Mijn eerste #Ocrelizumab infuus was erg heftig, fikse bijwerkingen en allergische reactie #doorbikkelen wij kunnen dat. Zolang het maar helpt, met de rest leren omgaan en mijn weg in zien te vinden. #multiplesclerose #ms

Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab

"A #WearingOff effect has been reported in people with #MultipleSclerosis receiving #ocrelizumab and other monoclonal antibodies. We sought to describe the real-world occurrence of wearing-off effect among people with MS in #Canada treated with ocrelizumab."
www.ijmsc.org/view/wearing...

"We describe 2 [PwMS] with arthralgias, myalgias & generalized weakness after #ocrelizumab infusion. After excluding infection & given temporality following infusion, [ #SerumSickness] was suspected. Steroids (& potent anti-inflammatory medications...) alleviated symptoms..." doi.org/10.7224/1537...

Infusion day again! So very grateful to get this amazing drug in my veins every six months. Stable MRIs since 2021 and no discernable progression. Science rules! 😁💉
#MS #MultipleSclerosis #Ocrevus #ocrelizumab

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis | Neurology Background and ObjectivesEarly treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS ...

#Ocrelizumab in Early-Stage Relapsing-Remitting #Multiple #Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial www.neurology.org/doi/10.1212/... #hvhebron #nimm